ARS Pharmaceuticals Inc. (SPRY)

AI Score

Unlock

14.49

-0.39 (-2.62%)

At close: Apr 21, 2025, 10:34 AM

ARS Pharmaceuticals Balance Sheet Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q4 2019
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	50.82M	39.66M	36.63M	56.01M	70.97M	60.53M	119.02M	87.86M	210.52M	37.32M	44.59M	233.99M	60.06M	300.66M	359.69M	374.2M	386.57M	9.98M
Short-Term Investments	263.2M	164.97M	182.12M	167.63M	157.39M	181.37M	133.19M	176.69M	63.86M	n/a	39.28M	19.86M	n/a	n/a	n/a	n/a	n/a	n/a
Long-Term Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	24.22M	44.22M	65.03M	40.29M	350K	350K	350K	550K
Other Long-Term Assets	8.42M	377K	n/a	233K	184K	2.48M	2.64M	2.86M	2.96M	22K	-24.2M	n/a	-65.01M	-1	n/a	n/a	-1	n/a
Receivables	9.16M	773K	n/a	n/a	795K	814K	962K	522K	n/a	n/a	35K	n/a	1K	n/a	n/a	n/a	n/a	n/a
Inventory	5.21M	715K	n/a	n/a	n/a	-814K	-962K	-522K	-1.01M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Current Assets	1.23M	2.68M	1.04M	1.46M	163K	n/a	n/a	n/a	n/a	1.18M	n/a	7.49M	n/a	4.7M	3.34M	4.14M	4.09M	552K
Total Current Assets	334.3M	208.79M	220.74M	226.01M	231.56M	244.47M	255.03M	267.35M	277.7M	39.09M	45.39M	261.33M	60.73M	305.36M	363.03M	378.35M	390.66M	10.53M
Property-Plant & Equipment	1.07M	935K	782K	814K	824K	917K	943K	982K	774K	615K	638K	6.91M	693K	6.92M	3.6M	3.5M	3.8M	4.57M
Goodwill & Intangibles	7.37M	7.5M	446K	528K	617K	690K	138K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Long-Term Assets	16.86M	8.81M	1.23M	1.57M	1.63M	4.09M	3.72M	3.84M	3.73M	637K	661K	51.14M	716K	47.21M	3.95M	3.85M	4.15M	5.12M
Total Assets	351.15M	217.6M	221.97M	227.58M	233.19M	248.56M	258.75M	271.19M	281.44M	39.73M	46.05M	312.47M	61.45M	352.56M	366.98M	382.2M	394.8M	15.65M
Account Payables	9.87M	8.28M	3.27M	839K	759K	2.97M	1.5M	2.58M	1.66M	126K	1.94M	2.63M	1.79M	1.72M	1.8M	4.37M	2.58M	3.52M
Deferred Revenue	557K	n/a	n/a	47K	4K	-2.97M	-9.65M	10K	283K	n/a	344K	n/a	1.46M	n/a	n/a	n/a	n/a	n/a
Short-Term Debt	42K	n/a	160K	217K	237K	235K	233K	232K	n/a	3.52M	3.5M	1.12M	3.48M	1.09M	958K	1.42M	1.74M	12.3M
Other Current Liabilities	2.29M	7.04M	1.63M	1.38M	843K	5.59M	6.24M	5.79M	1.46M	3.18M	693K	11.05M	660K	12.54M	12.79M	5.8M	5.28M	1.09M
Total Current Liabilities	23.44M	16.62M	6.72M	3.71M	2.39M	11.18M	10.05M	9.84M	5.44M	8.33M	7.46M	14.81M	8.19M	15.35M	15.55M	11.6M	9.6M	17.93M
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.28M	3.17M	n/a	4.93M	n/a	n/a	n/a	n/a	n/a
Other Long-Term Liabilities	70.92M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.85M	2.93M	76.12M	n/a	76.12M	n/a	n/a	-1	-1	n/a
Total Long-Term Liabilities	70.92M	n/a	n/a	n/a	37K	92K	146K	199K	3.1M	5.52M	82.62M	4.43M	84.53M	5.08M	1.78M	2.05M	2.33M	3.32M
Total Liabilities	94.36M	16.62M	6.72M	3.71M	2.43M	11.27M	10.2M	10.04M	8.55M	13.85M	90.08M	19.24M	92.72M	20.43M	17.33M	13.65M	11.93M	21.25M
Total Debt	42K	102K	160K	217K	274K	327K	379K	431K	481K	6.11M	7.25M	5.55M	9.03M	6.17M	2.74M	3.48M	4.07M	12.3M
Common Stock	10K	10K	10K	10K	10K	9K	9K	9K	9K	260K	260K	4K	257K	4K	4K	3K	3K	n/a
Retained Earnings	-123.31M	-173.24M	-154.11M	-141.59M	-131.3M	-124.14M	-109.27M	-91.9M	-76.94M	-62.51M	-55.93M	-210.84M	-42.26M	-162.75M	-140.1M	-115.6M	-96.73M	-63.79M
Comprehensive Income	n/a	n/a	-145K	-124K	49K	-161K	-180K	68K	407K	n/a	-1.55M	-1.25M	-326K	-34K	n/a	n/a	n/a	n/a
Shareholders Equity	256.8M	200.98M	215.24M	223.87M	230.76M	237.28M	248.55M	261.15M	272.89M	25.88M	-44.03M	293.23M	-31.27M	332.13M	349.65M	368.55M	382.88M	-5.6M
Total Investments	263.2M	164.97M	182.12M	167.63M	157.39M	181.37M	133.19M	176.69M	63.86M	n/a	39.28M	64.08M	65.03M	40.29M	350K	350K	350K	550K